Major RAS
MINOR
the mean USS of the 20 major RAS subjects before treatment was 40.2 ± 5.5 (range 33–53), and this was significantly reduced after 3 months treatment by 27.1% (p < 0.0002). The scores continued to decrease significantly after 6 and 9 months therapy (p < 0.03), but then stabilised. At the end of the 12 months therapy period, there was 48.7% improvement in the mean USS compared with the baseline visit (p < 0.001) (Table Analysis of the results in terms of the USS reduction below 20 showed that the overall response to treatment for minor RAS (32/47, 68%) was greater than for major RAS (21/39, 54%) but was not significantly different. There was substantial improvement in the USS after 6 months treatment in all three groups, and while the mean USS continued to reduce in the next 6 months of treatment, the benefit was statistically insignificant. Moreover, the greatest reduction in the mean USS after 12 months treatment was in the betamethasone mouthwash group for both minor and major RAS.